202857-53-2

Upstream product

• 33670-32-5 methoxymethyltriphenylphosphonium bromide 
• 202857-51-0 2,6-diisopropyl-4-(4-fluorophenyl)-5-pentyl-3-pyridinecarboxaldehyde 
• 124863-79-2 diethyl 4-(4-fluorophenyl)-2,6-diisopropylpyridine-3,5-dicarboxylate 
• 124863-80-5 ethyl 4-(4-fluorophenyl)-5-(hydroxymethyl)-2,6-diisopropylnicotinate 
• 202857-40-7 [4-(4-Fluoro-phenyl)-2,6-diisopropyl-5-((E)-pent-1-enyl)-pyridin-3-yl]-methanol 
• 202856-04-0 ethyl 2,6-Diisopropyl-4-(4-fluorophenyl)-3-formyl-pyridine-5-carboxylate 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 78168-82-8 ethyl 3-amino-4-methyl-pent-2-enoate 
• 202857-39-4 propyltriphenylphosphonium bromide 
• 202853-25-6 2,6-diisopropyl-3-hydroxymethyl-4-(4-fluorophenyl)-5-pentylpyridine 

Downstream Products

• 202857-52-1 2,6-Diisopropyl-3-(2-oxoethyl)-4-(4-fluorophenyl)-5-pentylpyridine 

Relevant academic research and scientific papers

Discovery of 5-Hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists

5-Hydroxyalkyl-4-phenylpyridines have been identified as a novel class of glucagon antagonists with potential utility for the treatment of diabetes. A lead structure with moderate activity was discovered through a high throughput screening assay. Structure-activity relationships led to the discovery of a potent antagonist, IC50=0.11 μM, more than 60-fold improvement over the lead structure.